The team’s work shows that early pathological processes in the brains of individuals who are genetically predisposed to develop Alzheimer’s disease are modulated by a pancreatic hormone called amylin. This study is the first to show that the brains of patients with familial AD accumulate amyloid-forming amylin secreted by the pancreas. “Our study suggests an alternative approach to reduce the progression of Alzheimer’s disease through the modulation of blood levels of amylin. In addition, the results of this study can point to the pancreatic hormone amylin as a potential missing molecular link between metabolic disorders and increased risk for Alzheimer’s disease. Specifically, amylin dysregulation contributes to both type-2 diabetes and Alzheimer’s disease.”
Pages
